This year, CRO/CMO companies have ushered in a wave of financing, with 16 in the first half of the year.
It is reported that CRO Company’s “Bao Sai Tu” announced the completion of the 543 million yuan D round of financing, the current round of the leading investors for the National Life Health Fund, SDIC entrepreneurship, C-round investor CMB International, Materia Medica capital continues to vote, The Biotech management team also participated in the investment. This round of funds will be used for market development, product development and service upgrades, as well as the construction of antibody production service bases.
Baisay is a comprehensive CRO that provides one-stop R&D services for preclinical research in biopharmaceuticals. The company has a model animal supply platform and a gene knockout CRO service, and there are two animal centers in the country. The company is headquartered in Beijing, with branches and offices in Haimen, Jiangsu, Boston, Shanghai, Wuhan, Guangzhou, Chengdu and other places.
National new drug research and development has ushered in a period of rapid development. With the growth of innovative pharmaceutical companies, CRO companies serving pharmaceutical companies have also ushered in development opportunities. In the medical resumption in 2019, this year’s CRO/CMO companies ushered in a wave of financing. As of June, the financing incident reached 16 pens.
It is understood that the business of Biotech is mainly covered by: model animal customized service, important model animal development and large-scale breeding and supply, in vivo pharmacological efficacy evaluation service, and antibody drug research and development outsourcing service. Next, the company will also extend the product line, hoping to fully cover the antibody drug research and development services, and expand to the antibody production process research and development and CMC services.
According to the public information, Bai’s Sai Tu has a total of 25 doctors and 48 masters in the pharmaceutical industry at home and abroad. Many of them have obtained senior titles in the pharmaceutical industry, and they have been engaged in research and development of gene knockout, human embryonic stem cells and virus analysis, and CRO. service.
Founder Dr. Shen Yuelei said: “We insist on investing a considerable proportion of sales revenue every year in research and development. In recent years, we have submitted more than 100 invention patent applications each year. All the animal models we provide to our customers have Independent intellectual property. We firmly believe that continuous R&D investment will be the key to the company’s consistently high quality products and services.”